Sixera Pharma Receives Rare Pediatric Disease Designation (RPDD) from FDA for SXR1096 for treatment of Netherton syndrome
Stockholm, July 5, 2022. The Swedish biotech company, Sixera Pharma (”Sixera”) today announced that the US Food and Drug Administration (FDA) has granted rare pediatric
July 5, 2022
No Comments
